Table 4.
Sensitivity Analyses for Serious Infection, Opportunistic Infection, and Herpes Zoster Outcomes: THIN Cohort
| Sensitivity Analysis Model by Outcome | Number of Patients | All Psoriasis HR (95% CI) |
Mild Psoriasis HR (95% CI) |
Moderate-to-Severe Psoriasis HR (95% CI) |
|
|---|---|---|---|---|---|
| No Psoriasis | Psoriasis | ||||
| Serious Infection | |||||
| Primary Model | 954,315 | 199,700 | 1.21 (1.18, 1.23) | 1.18 (1.16, 1.21) | 1.63 (1.52, 1.75) |
| Multiple Imputation | 954,315 | 199,700 | 1.20 (1.18, 1.23) | 1.18 (1.15, 1.21) | 1.63 (1.52, 1.75) |
| Exclude patients seen by GP less than once per year | 909,728 | 192,303 | 1.20 (1.18, 1.23) | 1.18 (1.15, 1.21) | 1.61 (1.50, 1.73) |
| Exclude IBD and RA | 943,052 | 194,047 | 1.21 (1.18, 1.23) | 1.19 (1.16, 1.21) | 1.64 (1.52, 1.76) |
| Exclude PsA | 954,315 | 189,622 | 1.20 (1.17, 1.23) | 1.18 (1.16, 1.21) | 1.71 (1.57, 1.86) |
| Exclude patients with history of infection | 366,203 | 89,312 | 1.25 (1.21, 1.30) | 1.23 (1.18, 1.28) | 1.73 (1.52, 1.98) |
| Exclude patients who had received immunosuppressive psoriasis treatments | 951,676 | 190,055 | 1.19 (1.16, 1.22) | 1.19 (1.16, 1.21) | 1.56 (1.35, 1.82) |
| Opportunistic Infection | |||||
| Primary Model | 954,315 | 199,700 | 0.91 (0.79, 1.04) | 0.87 (0.75, 1.00) | 1.57 (1.06, 2.34) |
| Multiple imputation | 954,315 | 199,700 | 0.91 (0.79, 1.05) | 0.87 (0.75, 1.00) | 1.61 (1.08, 2.39) |
| Exclude patients seen by GP less than once per year | 909,728 | 192,303 | 0.90 (0.79, 1.04) | 0.86 (0.75, 1.00) | 1.54 (1.03, 2.29) |
| Exclude IBD and RA | 943,052 | 194,047 | 0.92 (0.80, 1.06) | 0.89 (0.76, 1.03) | 1.64 (1.06, 2.53) |
| Exclude PsA | 954,315 | 189,622 | 0.91 (0.79, 1.04) | 0.87 (0.75, 1.01) | 1.66 (1.03, 2.68) |
| Exclude patients with history of opportunistic infection | 944,619 | 198,042 | 0.92 (0.79, 1.06) | 0.86 (0.74, 1.01) | 1.76 (1.18, 2.65) |
| Exclude patients who had received immunosuppressive psoriasis treatments | 951,676 | 190,055 | 0.88 (0.76, 1.02) | 0.88 (0.76, 1.02) | 1.17 (0.44, 3.12) |
| Herpes Zoster | |||||
| Primary Model | 954,315 | 199,700 | 1.08 (1.05, 1.11) | 1.07 (1.05, 1.10) | 1.17 (1.06, 1.30) |
| Multiple imputation | 954,315 | 199,700 | 1.08 (1.05, 1.11) | 1.09 (1.06, 1.13) | 1.20 (1.08, 1.33) |
| Exclude patients seen by GP less than once per year | 909,728 | 192,303 | 1.08 (1.05, 1.11) | 1.07 (1.04, 1.10) | 1.16 (1.05, 1.28) |
| Exclude IBD and RA | 943,052 | 194,047 | 1.08 (1.05, 1.11) | 1.08 (1.05, 1.11) | 1.12 (1.00, 1.26) |
| Exclude PsA | 954,315 | 189,622 | 1.08 (1.05, 1.11) | 1.08 (1.05, 1.11) | 1.16 (1.02, 1.32) |
| Exclude patients with history of herpes zoster | 913,982 | 192,249 | 1.07 (1.04, 1.10) | 1.07 (1.04, 1.10) | 1.19 (1.07, 1.32) |
| Exclude patients who had received immunosuppressive psoriasis treatments | 951,676 | 190,055 | 1.08 (1.05, 1.11) | 1.08 (1.05, 1.11) | 0.97 (0.76, 1.23) |